
GoodRx Holdings (GDRX) Stock Forecast & Price Target
GoodRx Holdings (GDRX) Analyst Ratings
Bulls say
GoodRx Holdings Inc. has revised its revenue growth expectations for 2024 to a mid-single-digit percentage (MSD%), reflecting an improvement from its prior range of approximately 2.1-5.4%, indicating a potential for stronger performance than consensus estimates. This optimistic outlook is supported by a superior margin profile and increased utilization from seasonal factors and strategic initiatives such as retailer direct contracting. Furthermore, the company's 4Q23 revenue exceeded consensus by 2.7%, reinforcing the positive trajectory and potential for re-accelerated growth in both its membership and manufacturer solutions business.
Bears say
GoodRx Holdings Inc. faces multiple headwinds, including a significantly reduced revenue growth outlook for 2024 projected at only 2-5%, compounded by ongoing issues with declining volumes at Kroger and uncertainty surrounding the company's revenue guidance, which was approximately 6.5% below consensus estimates. Additionally, the company's growth may be adversely affected by the delayed launch of important programs, such as the ESI program and the Caremark program, which could limit its competitive positioning in the market. Furthermore, changes in the regulatory environment and the potential for increased competition from employers offering free generics threaten GoodRx's ability to sustain its revenue and profitability moving forward.
This aggregate rating is based on analysts' research of GoodRx Holdings and is not a guaranteed prediction by Public.com or investment advice.
GoodRx Holdings (GDRX) Analyst Forecast & Price Prediction
Start investing in GoodRx Holdings (GDRX)
Order type
Buy in
Order amount
Est. shares
0 shares